Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

“I think I’m a bit heavy for it.” This was my response when a colleague suggested that the Triumph Scrambler 400 X looked right up my street, and I was only half joking. At and 17st (ish ...

As soon as I saw the Triumph Scrambler 400 X I wanted a go. It looked somehow more grown up than its simultaneously launched stablemate, the Speed 400, and I thought a lightweight single would be ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

In September, Kisqali was approved by the FDA in this setting 5; at ESMO 2024, an updated analysis from NATALEE was presented, showing a deepening invasive disease-free survival benefit 6 “One-third ...

Kyle Larson comes into this one as the obvious driver to beat with three wins and two runner-up results in seven races here with Hendrick Motorsports. However, there will be 36 other participants ...

Sunday’s South Point 400 marks the first race of the Round of 8 for the NASCAR Cup Series. With the level of uncertainty that Talladega and the Charlotte Roval bring to teams, Championship ...

Oct 20, 2024; Las Vegas, Nevada, USA; NASCAR Cup Series driver Ty Gibbs (54) leads the field during the South Point 400 at Las Vegas Motor Speedway. Mandatory Credit: Gary A. Vasquez-Imagn Images The ...